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Abstract: We report the cloning and catalytic activity of a β-carbonic anhydrase (CA, EC 4.2.1.1),
isolated from the pathogenic protozoan Entamoeba histolytica, EhiCA. This enzyme has a high catalytic
activity for the physiologic CO2 hydration reaction, with a kcat of 6.7 × 105 s−1 and a kcat/Km
of 8.9 × 107 M−1 × s−1. An anion inhibition study of EhiCA with inorganic/organic anions and
small molecules revealed that fluoride, chloride, cyanide, azide, pyrodiphosphate, perchlorate,
tetrafluoroborate and sulfamic acid did not inhibit the enzyme activity, whereas pseudohalides
(cyanate and thiocyanate), bicarbonate, nitrate, nitrite, diethyldithiocarbamate, and many complex
inorganic anions showed inhibition in the millimolar range (KIs of 0.51–8.4 mM). The best EhiCA
inhibitors were fluorosulfonate, sulfamide, phenylboronic acid and phenylarsonic acid (KIs in the
range of 28–86 µM). Since β-CAs are not present in vertebrates, the present study may be useful for
detecting lead compounds for the design of effective enzyme inhibitors, with potential to develop
anti-infectives with alternative mechanisms of action.
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1. Introduction
The carbonic anhydrases (CAs, EC 4.2.1.1) are enzymes that effectively catalyze the reaction
between CO2 and water, yielding bicarbonate (HCO3−) and protons (H+). They are among the fastest
catalysts known in nature [1–3]. CAs are multifunctional enzymes, which play a central role in different
physiological, biochemical, and metabolic processes, such as acid-base homeostasis; respiratory gas
exchange; electrolyte secretion; and biosynthesis of urea, glucose, fatty acids, and carbamoyl phosphate.
They are also vital in ionic transport, muscular contraction (in vertebrates), and photosynthesis
(in plants and algae). Seven distinct genetic families (i.e., the α, β, γ, δ, ζ, η, and θ class CAs) are known
to date, with a wide distribution in organisms throughout the tree of life [4–10]. The CA classes do not
share any significant sequence and structural identity, being a paradigmatic example of convergent
evolution at the molecular level [1–3].
The first β-CA was discovered in 1939, but it took several decades until it was recognized
as evolutionarily and structurally distinct from the previously studied CAs, those belonging to
the α-class [11]. After the 1990s, many new β-CAs were discovered in the genomes of various
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organisms [11]. Based on current knowledge, these enzymes are found in photosynthetic organisms,
eubacteria, yeasts, and Archaea [11–13]. Later on, it was discovered that they are also present in
the genomes of insects, nematodes, and protozoans, but not in mammals [14]. Therefore, β-CAs are
considered promising target enzymes for antiparasitic drugs [15–17]. The physiological significance of
β-CAs is somehow ambiguous in most organisms studied so far, because frequently there are more
than one enzyme class present [1–3,14–18]. However, β-CAs were shown to have important roles (for
instance, in providing bicarbonate/CO2 for the photosynthetic enzyme Rubisco in the chloroplasts of
many plants/algae [11,17,18]). Helicobacter pylori contains only one α- and one β-CA, whose inhibition
with sulfonamides impairs the growth of the pathogen in vitro and in vivo [13,15]. The physiological
relevance of β-CAs in many organisms, including protozoans belonging to the Amoebozoas, is yet
to be discovered. However, in Leishmania spp., a β-class CA enzyme (LdcCA) was recently shown
to be a potential drug target [19–21]. Indeed, the inhibition of protozoan β-CAs with sulfonamides,
formulated as nanoemulsions, had a profound effect on the survival and growth of L. amazonensis and
L. infantum, two species which provoke serious disease in the tropical and subtropical countries [21].
Entamoeba histolytica is a pathogenic protozoan human parasite causing amebiasis, which can
be expressed as colitis or abscess of intestines or liver [22,23]. The common symptoms are diarrhea,
colitis, and dysentery, but the majority of infections are asymptomatic [22,23]. E. histolytica is ingested
with contaminated food or water as mature cysts, which excystate in the small intestine. The released
trophozoites will then invade the large intestine [22]. E. histolytica is capable of lysing human tissues,
killing immune effector cells by contact-dependent cytolysis [22,24]. The parasite has many virulence
mechanisms, as it can adhere to host cells with multi-subunit GalGalNAc lectins, degrade the host
extracellular matrix with cysteine proteases, and lyses target cells with amoebapores [25]. The invasive
forms of the infection generally include cyst formation in the liver, which can lead to complications
such as pleural effusion, due to the rupture of the cyst [22,26]. Rarely, they also disseminate through
other extraintestinal organs (e.g., the brain or pericardium) [22,23]. Although there are effective
medications for treating E. histolytica, therapies for the invasive forms produce many adverse side
effects [22,23], and there are additional limitations to such therapies, among which is an increasing
prevalence of resistance to commonly used drugs, which emphasizes the need for new drug targets
against this protozoan [23,25]. Thus, we decided to clone and investigate in detail the β-CA present
in this pathogenic protozoan. Here we report the cloning, purification, investigation of the catalytic
activity, and the anion inhibition profile of the recombinant enzyme belonging to the β-class, identified
in the genome of the pathogenic protozoan E. histolytica, denominated EhiCA.
2. Results and Discussion
We produced the β-CA of E. histolytica, EhiCA, in the E. coli production system (see Experimental
for details) as reported earlier for other CAs, such as hCA VII [19]. As a result, we obtained a 21 kDa
protein, which was confirmed to be the right β-CA with mass spectrometry (MS) and SDS-PAGE
(Figure 1). Furthermore, atomic absorption spectroscopy allowed us to determine the presence of one
zinc ion per polypeptide chain (data not shown), which confirmed the MS data.
We measured the catalytic activity of the recombinant EhiCA (for the CO2 hydration reaction) [27],
comparing its kinetic parameters with those of other such enzymes, belonging to the α-class, such
as hCA I and II, (h stands for human isoform). Table 1 shows that EhiCA has a significant catalytic
activity (for the physiologic reaction, CO2 hydration to bicarbonate and protons), with a kcat of
6.7 × 105 s−1 and a kcat/Km of 8.9 × 107 M−1 × s−1, being thus 1.8 times more effective as a
catalyst, compared to the slow human isoform hCA I (considering the kcat/Km values). Furthermore,
like most enzymes belonging to the CA superfamily, EhiCA was inhibited by acetazolamide
(AZA, 5-acetamido-1,3,4-thiadiazole-2-sulfonamide): A standard, clinically used sulfonamide CA
inhibitor [1–3]. It can be observed that, similar to hCA I, EhiCA was inhibited in the high nanomolar
range by this compound, with an inhibition constant KIs of 509 nM (Table 1).
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Figure 1. SDS PAGE of the β-CA from E. histolytica (EhiCA) showing a 21/25 kDa doublet 
polypeptide and additional polypeptides of about 50 and 75 kDa (arrows). Left lane: Standard Mw 
markers. The dimer and the trimer of EhiCA are also seen (arrows), as reported for other β-CAs cloned 
and purified earlier [11–15]. 
In order to rationalize the effective catalytic activity of EhiCA, we aligned the amino acid 
sequence of this protein with that of other β-CAs, such as those from the pathogenic bacteria 
Haemophilus influenzae, Vibrio cholerae, Escherichia coli, Salmonella typhimurium, two isoforms from 
Mycobacterium tuberculosis [11,27–29], and the cyanobacterium Synechocystis sp. PCC 6803 [30] (Figure 
2). 
As seen in Figure 2, EhiCA (as all β-CAs investigated to date) has the conserved three zinc(II) 
ligands, Cys50, His103, and Cys106 (the fourth ligand is presumably a water molecule/hydroxide 
ion), as well as the catalytic dyad constituted by the pair Asp52–Arg54 (also conserved in all enzymes 
belonging to this class) [11–15,27–30], which contributes to the enhancement of the nucleophilicity of 
the water coordinated to the metal ion. The presence of these conserved amino acids, and all the 
structural elements connected to them, may explain the catalytic activity of EhiCA reported in this 
paper (Table 1). 
Figure 1. SDS PAGE of the β-CA from E. histolytica (EhiCA) showing a 21/25 kDa doublet polypeptide
and additional polypeptides of about 50 and 75 kDa (arrows). Left lane: Standard Mw markers.
The dimer and the trimer of EhiCA are also seen (arrows), as reported for other β-CAs cloned and
purified earlier [11–15].
In to rationalize the eff ctive cataly ic activity of EhiCA, we align d the amino acid sequence
of this pr tein with hat of other β-CAs, such as those from e pathogenic bacteria Haemophilus
influenzae, Vibrio chol rae, Escherichi coli, Salmonella typhimurium, wo sofor s from Mycobacte ium
tuberculosis [11,27–29], and the cyanobacterium Synechocystis sp. PCC 6803 [30] (Figure 2).
Table 1. Kinetic parameters for the CO2 hydration reaction catalyzed by the human cytosolic
isozymes hCA I and II (α-class CAs) at 20 ◦C and pH 7.5 in 10 mM HEPES buffer and 20 mM
Na2SO4, and the β-CA EhiCA form E. histolytica measured at 20 ◦C, pH 8.3 in 20 mM TRIS
buffer and 20 mM NaClO4. Inhibition data with the clinically used sulfonamide acetazolamide
(5-acetamido-1,3,4-thiadiazole-2-sulfonamide) are also provided [31].
Enzyme Activity Level Class kcat (s−1) Km (mM)
kcat/Km
(M−1 × s−1)
KI
(Acetazolamide) (nM)
hCA I moderate α 2.0 × 105 4.0 5.0 × 107 250
hCA II very high α 1.4 × 106 9.3 1.5 × 108 2
EhiCA high β (6.7 ± 0.2) × 105 7.5 ± 0.08 (8.9 ± 0.1) × 107 509
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Figure 2. Multi-alignment of the amino acid sequences of the β-CAs from M. tuberculosis (isoform 
MTCA1_MYCTU), Synechocystis sp. (SYNY3), V. cholerae (VIBCL), H. influenzae (HAEIN), E. coli 
(ECOLI), S. typhimurium (SALTY), E. histolytica (ENTHI), and M. tuberculosis (isoform MTCA2_ 
MYCTU) [11,27–30]. Conserved amino acids depicted by an asterisk (*), semiconserved ones by (.) or 
(:). 
Table 1. Kinetic parameters for the CO2 hydration reaction catalyzed by the human cytosolic isozymes 
hCA I and II (α-class CAs) at 20 °C and pH 7.5 in 10 mM HEPES buffer and 20 mM Na2SO4, and the 
β-CA EhiCA form E. histolytica measured at 20 °C, pH 8.3 in 20 mM TRIS buffer and 20 mM NaClO4. 
Inhibition data with the clinically used sulfonamide acetazolamide (5-acetamido-1,3,4-thiadiazole-2-
sulfonamide) are also provided [31]. 
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Figure 2. Multi-alignment of the amino acid sequences of the β-CAs from M. tuberculosis
(isoform MTCA1_MYCTU), Synechocystis sp. (SYNY3), V. cholerae (VIBCL), H. influenzae (HAEIN),
E. coli (ECOLI), S. typhimurium (SALTY), E. histolytica (ENTHI), and M. tuberculosis (isoform
MTCA2_ MYCTU) [11,27–30]. Conserved amino acids depicted by an asterisk (*), semiconserved
ones by (.) or (:).
As seen in Figure 2, EhiCA (as all β-CAs investigated to date) has the conserved three zinc(II)
ligands, Cys50, His103, and Cys106 (the fourth ligand is presumably a water molecule/hydroxide
ion), as well as the catalytic dyad constituted by the pair Asp52–Arg54 (also conserved in all enzymes
belonging to this class) [11–15,27–30], which contributes to the enhancement of the nucleophilicity
of the water coordinated to the metal ion. The presence of these conserved amino acids, and all the
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structural elements connected to them, may explain the catalytic activity of EhiCA reported in this
paper (Table 1).
We also investigated the inhibition of EhiCA with a set of inorganic simple and complex
anions, as well as small organic molecules known [11–15,27–30] to interact with CAs, such as
diethyl-dithiocarbamate, sulfamide, sulfamic acid, phenyboronic and phenylphosphonic acid, among
others (Table 2).
Table 2. Inhibition constants of anionic inhibitors against the α-CA isoforms hCA II and hCA I, as well
as the β-class protozoan enzyme EhiCA, for the CO2 hydration reaction at 20 ◦C [31].
Inhibitor § KI [mM] #
hCA II hCA I EhiCA
F− >300 >300 >100
Cl− 200 6.0 >100
Br− 63 4.1 36.8
I− 26 0.3 7.4
CNO− 0.03 0.0007 0.77
SCN− 1.6 0.2 7.9
CN− 0.02 0.0005 >100
N3− 1.51 0.0012 >100
HCO3− 85 12 0.28
CO32− 73 15 2.4
NO3− 35 7.0 3.6
NO2− 63 8.4 1.7
HS− 0.04 0.0006 6.9
HSO3− 89 18 11.5
SO42− >200 63 21.6
SnO32− 0.83 0.57 0.51
SeO42− 112 118 6.0
TeO42− 0.92 0.66 0.61
P2O74− 48.50 25.8 >100
V2O74− 0.57 0.54 >100
B4O72− 0.95 0.64 0.29
ReO4− 0.75 0.11 7.1
RuO4− 0.69 0.10 7.0
S2O82− 0.084 0.11 8.4
SeCN− 0.086 0.085 0.87
CS32− 0.0088 0.0087 6.0
Et2NCS2− 3.1 0.00079 0.51
ClO4− >200 >200 >100
BF4− >200 >200 >100
FSO3− 0.46 0.79 0.086
PF6− >200 >200 >100
CF3SO3− >200 >200 >100
NH(SO3)22− 0.76 0.31 2.2
H2NSO2NH2 1.13 0.31 0.028
H2NSO3H 0.39 0.021 >100
Ph-B(OH)2 23.1 38.6 0.047
Ph-AsO3H2 49.2 31.7 0.038
§ As sodium salt; # Errors were in the range of 3–5% of the reported values, from three different assays.
The following observations can be made from the inhibition data shown in Table 2:
(i) The anions which did not show inhibitory activity against EhiCA were fluoride, chloride,
and, surprisingly, cyanide and azide, which are highly effective inhibitors of α-CAs such as hCA
I and II [32]; pyrodiphosphate and divanadate; perchlorate, tetrafluroborate, hexafluorophosphate,
and triflate (which usually do not significantly inhibit any CA [32]); and, again surprisingly, sulfamic
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acid. All these compounds did not show significant inhibition up to a 100 mM concentration in the
assay system.
(ii) The most effective EhiCA inhibitors were sulfamide (which is structurally highly similar to
sulfamic acid, except that the pKa of the two compounds is highly different) [33,34] and fluorosulfonate,
as well as phenylboronic acid and phenylarsonic acid, which showed KIs in the range of 28–86 µM
(Table 2). As seen in Table 2, many of these small molecules/anions also act as inhibitors of hCA I and
II, but with a rather different efficacy [33].
(iii) Several anions, such as cyanate, selenocyanate, bicarbonate, stannate, tellurate, tetraborate,
and N,N-diethyl-dithiocarbamate were also sub-millimolar EhiCA inhibitors, with KIs in the range of
0.28–0.87 mM. Some of these compounds are typical metal complexing agents (cyanate, selenocyanate,
N,N-diethyt-dithiocarbamate), and their propensity to bind the zinc ion in this β-CA explains
these inhibitory activities. However, others, (among which are bicarbonate, stannate, tellurate,
and tetraborate) show less affinity to act as metal complexing anions [32]. The inhibitory action
of bicarbonate, one of the reaction products/substrates of the CA, is particularly interesting, possibly
indicating that the enzyme is not acting as a highly efficient bicarbonate dehydratase, but instead
that the CO2 hydratase activity might be crucial during the life cycle of this protozoan. However,
this speculation needs careful validation.
(iv) Many anions acted as low millimolar EhiCA inhibitors. They include iodide, thiocyanate,
carbonate, nitrate, nitrite, hydrogensulfide, selenite, perrhenate, perruthenate, peroxydisulfate,
trithiocarbonate, and imidosulfonate (KIs in the range of 1.7–8.4 mM).
(v) Anions with a less effective inhibitory action against EhiCA were bromide, bisulfite, and sulfate,
with KIs in the range of 11.5–365.8 mM (Table 1).
3. Materials and Methods
3.1. Vector Construction
We produced the EhiCA as a recombinant protein in E. coli. The DNA sequence was retrieved
from UniProt, and modified for recombinant protein production. We provided the sequence of the
insert, and the actual construction of the plasmid vector was performed by GeneArt (Invitrogen,
Regensburg, Germany). The structure of the insert was specifically modified for production in E. coli.
The insert was ligated into a modified plasmid vector, pBVboost.
3.2. Production of the Protein
The freeze-dried plasmid was prepared, according to manufacturer’s manual. Deep-frozen BL21
Star™ (DE3) cells (Invitrogen, Carlsbad, CA, USA) were slowly melted on ice. Once melted, 25 µL
of the cell suspension and 1 µL of the plasmid solution were combined. The suspension was kept
on ice for 30 min. Heat shock was performed by submerging the suspension-containing tube into
42 ◦C water for 30 s, and was then incubated on ice for 2 min. To the tube 125 µL of S.O.C Medium
(Invitrogen, Carlsbad, CA, USA) was added, and the tube was incubated for 1 h with constant shaking
(200 rpm) at 37 ◦C. Growth plates (gentamycin-LB medium, ratio 1:1000) were prewarmed at 37 ◦C
for 40 min. Then, 20 µL and 50 µL of suspension was spread on two plates which were incubated
overnight at 37 ◦C. A volume of 5 mL preculture was prepared by inoculating single colonies from
growth plates onto an LB medium with gentamycin (ratio 1:1000). It was then incubated overnight at
37 ◦C with constant shaking (200 rpm). The production was executed according to pO-stat fed batch
protocol, which is essentially as described in Määttä et al. [35]. There were some alterations to the
previously described protocol: The fermentation medium did not contain glycerol, as the cell line used
did not require it. The induction of the culture was performed with 1 mM IPTG, 12 h after starting the
fermentation. Temperature was decreased to 25 ◦C at the time of the induction. Culturing was stopped
after 12 h of the induction with the OD 34 (A600). The cells were collected by centrifugation, and the
wet weight of the cell pellet was 303 g. The fermentation was performed by the Tampere facility
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of Protein Services (PS). The cell pellet (approximately 35 g) was suspended in 150 mL of binding
buffer containing 50 mM Na2HPO4, 0.5 M NaCl, 50 mM imidazole, and 10% glycerol (pH 8.0), and the
suspension was homogenized with an EmulsiFlex-C3 (AVESTIN, Ottawa, Canada) homogenizer.
The lysate was centrifuged at 13,000× g for 15 min at 4 ◦C, and the clear supernatant was mixed with
HisPur™ Ni-NTA Resin (Thermo Fisher Scientific, Waltham, MA, USA) and bound to the resin for
2 h at room temperature on the magnetic stirrer. Then resin was washed with the binding buffer and
collected onto an empty column with an EMD Millipore™ vacuum filtering flask (Merck, Kenilworth,
NJ, USA) and filter paper. The protein was eluted from the resin with 50 mM Na2HPO4, 0.5 M NaCl,
350 mM imidazole, and 10% glycerol (pH 7.0). The protein was re-purified with TALON® Superflow™
cobalt resin (GE Healthcare, Chicago, IL, USA). The eluted protein fractions were diluted with binding
buffer (50 mM Na2HPO4, 0.5 M NaCl, and 10% glycerol pH 8.0), so that the imidazole concentration
was under 10 mM. The protein binding and elution was performed as described above. The purity
of the protein was determined with gel electrophoresis (SDS-PAGE), and visualized with PageBlue
Protein staining solution (Thermo Fisher Scientific, Waltham, MA, USA). Protein fractions were pooled
and concentrated with 10 kDa Vivaspin® Turbo 15 centrifugal concentrators (Sartorius™, Göttingen,
Germany) at 4000× g at 4 ◦C. Buffer exchange in 50 mM TRIS (pH 7.5) was done using the same
centrifugal concentrators. His-tag was cleaved from the purified protein by Thrombin CleanCleave Kit
(Sigma-Aldrich, Saint Louis, MO, USA), according to manufacturer’s manual.
3.3. CA Activity and Inhibition Measurements
An Sx.18Mv-R Applied Photophysics (Oxford, UK) stopped-flow instrument has been used to
assay the catalytic activity of various CA isozymes for the CO2 hydration reaction [31]. Phenol red (at
a concentration of 0.2 mM) was used as indicator (working at the absorbance maximum of 557 nm).
Following the CA-catalyzed CO2 hydration reaction, 10 mM Hepes (pH 7.5, for α-CAs) or TRIS (pH
8.3, for β-CAs) as buffers, and 0.1 M NaClO4 (for maintaining constant ionic strength), were used for a
period of 10 s at 25 ◦C. The CO2 concentrations ranged from 1.7 to 17 mM, for the determination of the
kinetic parameters and inhibition constants. For each inhibitor, at least six traces of the initial 5–10% of
the reaction were used for determining the initial velocity. The uncatalyzed rates were determined in
the same manner, and subtracted from the total observed rates. Stock solutions of inhibitors (10 mM)
were prepared in distilled and deionized water, and dilutions of up to 1 µM were done thereafter with
the assay buffer. Enzyme and inhibitor solutions were pre-incubated together for 15 min (standard
assay at room temperature) prior to assay, in order to allow for the formation of the enzyme–inhibitor
complex. The inhibition constants were obtained by non-linear least-squares methods, using PRISM 3
and the Cheng–Prusoff equation [36–38].
4. Conclusions
In the search for alternative drug targets against anti-protozoan agents, we report the cloning
and catalytic activity of a β-CA from Entamoeba histolytica, EhiCA, the etiological agent of diarrhea
and amebic liver abscesses. This new enzyme has a high catalytic activity for the physiologic CO2
hydration reaction, with a kcat of 6.7 × 105 s−1 and a kcat/Km of 8.9 × 107 M−1 × s−1. An anion
inhibition study of EhiCA with inorganic/organic anions and small molecules was performed,
in order to detect interesting leads for effective inhibitors. Fluoride, chloride, cyanide, azide,
pyrodiphosphate, perchlorate, tetrafluoroborate, and sulfamic acid did not inhibit the enzyme activity,
whereas pseudohalides (cyanate and thiocyanate), bicarbonate, nitrate, nitrite, diethyldithiocarbamate,
and many complex inorganic anions showed inhibition in the millimolar range (KIs of 0.51–8.4 mM).
The best EhiCA inhibitors were fluorosulfonate, sulfamide, phenylboronic acid, and phenylarsonic
acid (KIs in the range of 28–86 µM). Since β-CAs are not present in vertebrates, the present study may
be useful for detecting lead compounds for the design of effective enzyme inhibitors, with potential to
develop anti-infectives with alternative mechanisms of action.
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